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Mammalian protein N-linked glycosylation is critical for glycopro-
tein folding, quality control, trafficking, recognition, and function.
N-linked glycans are synthesized from Glc3Man9GlcNAc2 precur-
sors that are trimmed and modified in the endoplasmic reticulum
(ER) and Golgi apparatus by glycoside hydrolases and glycosyl-
transferases. Endo-α-1,2-mannosidase (MANEA) is the sole endo-
acting glycoside hydrolase involved in N-glycan trimming and is
located within the Golgi, where it allows ER-escaped glycoproteins
to bypass the classical N-glycosylation trimming pathway involv-
ing ER glucosidases I and II. There is considerable interest in the
use of small molecules that disrupt N-linked glycosylation as ther-
apeutic agents for diseases such as cancer and viral infection. Here
we report the structure of the catalytic domain of human MANEA
and complexes with substrate-derived inhibitors, which provide
insight into dynamic loop movements that occur on substrate
binding. We reveal structural features of the human enzyme that
explain its substrate preference and the mechanistic basis for ca-
talysis. These structures have inspired the development of new
inhibitors that disrupt host protein N-glycan processing of viral
glycans and reduce the infectivity of bovine viral diarrhea and
dengue viruses in cellular models. These results may contribute
to efforts aimed at developing broad-spectrum antiviral agents
and help provide a more in-depth understanding of the biology
of mammalian glycosylation.
glycosylation | structural biology | secretory pathway | enzyme | antiviral
Asparagine (N)-linked glycosylation is a protein modificationthat is widespread in eukaryotes and is essential for protein
quality control and trafficking (1). N-linked glycans contribute to
protein structure and stability, receptor targeting, development,
and immune responses (2). N-linked glycosylation occurs in the
secretory pathway and is initiated in the lumen of the endo-
plasmic reticulum (ER) through cotranslational transfer of the
triantennary Glc3Man9GlcNAc2 glycan from a lipid linked pre-
cursor (2–5) (Fig. 1). The formation of mature glycoproteins re-
quires the removal of the glucose residues, typically through the
action of α-glucosidases I and II, which are localized within the
rough ER. However, in most cell lines and in human patients,
genetic disruption of α-glucosidase I or II or inhibition of their
activities does not prevent the formation of mature glycoproteins
because of the action of Golgi endo-α-1,2-mannosidase (MANEA;
mannosidase, endo-alpha) (6), which provides a glucosidase-
independent pathway for glycoprotein maturation termed the
endomannosidase pathway (7).
MANEA is present chiefly in cis/medial Golgi (84%) and the
ER-Golgi intermediate compartment (15%) (8) and allows trim-
ming of glucosylated mannose residues from Glc1–3Man9GlcNAc2
structures and B and C branch mannose-trimmed variants (see
Fig. 1 for a definition of N-glycan branches). The action of
MANEA on Glc1–3Man9GlcNAc2 results in cleavage of the
glucosylated mannose in the A branch, releasing Glc1–3Man and
Man8GlcNAc2; human MANEA acts faster on Glc1Man than on
Glc2,3Man glycans (9). The endomannosidase pathway allows
processing of ER-escaped, glucosylated high-mannose glycans on
glycoproteins that fold independently of the calnexin/calreticulin
folding cycle, allowing them to rejoin the downstream N-glycan
maturation pathway. In murine BW6147 cells under normal con-
ditions, flux through the endomannosidase pathway accounts for
approximately 15% of total flux through the secretory pathway
(10); under conditions of glucosidase blockade through knockout
or inhibition, MANEA can support as much as 50% of the normal
glycoprotein flux, depending on cellular expression levels (10).
MANEA activity accounts for the accumulation of Glc3Man tet-
rasaccharide in the urine of a neonate suffering from CDG-IIb, a
rare genetic disease caused by a deficiency of ER glucosidase
I (11).
Most enveloped viruses (e.g., coronaviruses, retroviruses,
ebolaviruses, hepatitis B virus [HBV], influenza viruses) contain
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glycoproteins within their envelope (12). Glycosylation is achieved
by coopting host cell glycosylation machinery during replication.
Substantial efforts have been deployed in the use of inhibitors of
α-glucosidases I and II as antivirals (e.g., N-butyldeoxynojirimycin,
6-O-butanoylcastanospermine) for the treatment of HIV/AIDS
(13), dengue (14, 15), and HBV (16, 17) (reviewed in refs. 18–20).
Inhibition of host glycosylation pathways, in particular ER glu-
cosidases I and II and Golgi mannosidase I, interferes with the
viral lifecycle by impairing protein folding and quality control,
inducing the unfolded protein response or mistrafficking of viral
glycoproteins. These changes can lead to impairment of secretion
(17, 21–23) or fusion (24–26) or evasion of host immunity (27). In
the case of HBV, when glucosidases are inhibited, mature HBV
viral glycoproteins are still produced through the alternative pro-
cessing provided by the endomannosidase pathway (23). However,
the contribution of the endomannosidase pathway to viral protein
assembly under normal conditions remains poorly studied, and the
antiviral activity of inhibitors targeting MANEA has not yet been
evaluated.
The Homo sapiens endo-α-1,2-mannosidase gene, MANEA, is
located on chromosome 6. The MANEA gene gives rise to three
transcripts, only one of which encodes the complete protein
product, MANEA. MANEA is categorized as a member of the
glycoside hydrolase (GH) family 99 in the Carbohydrate-Active
enZyme (CAZy) database (28), which also contains bacterial
endo-α-1,2-mannanases from Bacteroides xylanisolvens (BxGH99)
and Bacteroides thetaiotaomicron (BtGH99) that act on related
structures within yeast mannans and that share ∼40% identity with
MANEA (29–31).MANEA encodes a 462-aa protein that consists
of a single-pass type II membrane protein with a transmembrane
helix followed by a stem region, followed by the catalytic domain
(32). Here we reveal the structure of the catalytic domain of
human MANEA. Through complexes with substrate, we show
the architecture of the binding groove and identify key catalytic
residues. We report structures with MANEA inhibitors that
were designed based on the structure of the glucosylated high-
mannose N-glycan. Finally, we show that inhibitors of MANEA
act as antiviral agents against bovine viral diarrheal virus
(BVDV) and dengue virus (DENV), confirming that MANEA is an
antiviral target.
Results
Expression and Activity of Human MANEA GH99. To obtain soluble
MANEA protein for structure and function studies to inform
inhibitor design, attempts were made to express the gene. A
truncated gene for MANEA, consisting of the catalytic domain
beyond the stem domain (i.e., residues 98 to 462, hereinafter
MANEA-Δ97), was synthesized in codon-optimized form. Ex-
pression trials in Escherichia coli BL21(DE3) cells yielded only
insoluble protein, but we were inspired by a report of soluble
expression using cold-shock promotors (pCold-I vector) and
coexpression of GroEL chaperones (33). Optimal yields of
Fig. 1. Simplified pathway for biosynthesis of N-linked glycans through the classical and endomannosidase pathways. En bloc transfer of the preformed
Glc3Man9GlcNAc2 tetradecasaccharide (branches labeled A/B/C) from the dolichol precursor occurs cotranslationally to Asn residues within the consensus
sequence Asn-Xxx-Ser/Thr. Trimming of glucose residues can be achieved through the classical pathway involving sequential action of α-glucosidases I and II.
Alternatively, MANEA provides a glucosidase-independent pathway for glycoprotein maturation, through cleaving the glucose-substituted mannose residues.
ER mannosidase I resides in quality control vesicles (QCV) (43). ER-associated degradation of terminally misfolded glycoproteins is omitted.










































soluble MANEA-Δ97 were obtained using Terrific Broth sup-
plemented with glycerol and 20 mM MgCl2, affording ∼2 to
3 mg L−1 (SI Appendix, Fig. S1A and Experimental Procedures).
The recombinant protein was purified using the encoded
N-terminal His6-tag and was stable, with a Tm of 50 °C (SI Appendix,
Fig. S1B).
Treatment of GlcMan9GlcNAc2 with recombinant MANEA-
Δ97 released α-Glc-1,3-Man and Man8GlcNAc2 (SI Appendix,
Fig. S1C). Enzyme kinetics were measured using α-Glc-1,3-
α-Man-1,2-α-Man-1,2-α-Man-OMe (GlcMan3OMe) as substrate
with a coupled assay in which the product α-1,2-Man-ManOMe is
hydrolyzed by α-mannosidase and the resultant mannose quanti-
fied using aD-mannose/D-fructose/D-glucose detection kit (Megazyme)
(30). MANEA-Δ97 hydrolyzed GlcMan3OMe with a kcat of 27.7 ±
1.0 min−1 and a KM of 426 ± 33 μm (kcat/KM of 65 mM
−1 min−1) (SI
Appendix, Fig. S1D). The catalytic efficiency is similar to that dis-
played by BtGH99 on the epimeric Man4OMe substrate (KM =
2.6 mM; kcat = 180 min
−1; kcat/KM = 69 mM
−1 min−1) (30). The
E404Q variant of MANEA-Δ97 was inactive on this substrate,
consistent with the proposed mechanism (34).
Development of MANEA Inhibitors. GlcDMJ, a cell-permeable in-
hibitor of MANEA (35, 36), is composed of the well-known
mannosidase iminosugar inhibitor deoxymannojirimycin (DMJ)
modified with a glucosyl residue at the 3-position to enhance
specificity and binding to MANEA by mimicking the substrate
and benefitting from substrate-enzyme contacts in the −2 subsite
(Fig. 2). The related compound GlcIFG (31), which is also cell-
permeable (37), was developed through a similar approach ap-
plied to the azasugar isofagomine (IFG). Similarly, ManIFG was
synthesized to match the substrate stereochemistry of yeast man-
nan and is a superior inhibitor of bacterial endo-α-1,2-mannanases
(30). Because glucosylated mannans are substrates for α-glucosidase
II, GlcDMJ and GlcIFG may potentially be degraded in cell-based
systems (38), leading to loss of inhibition. Examination of the three-
dimensional (3D) X-ray structure of α-glucosidase II in complex
with N-butyldeoxynojirimycin reveals that binding of the sugar-
shaped heterocycle involves a pocket-like active site that will not
readily accommodate additional substituents (39). Conversely, it
is known that MANEA can cleave Glc1–3Man substrates in which
a substituent is tolerated at the 3-position of the glucosylated
mannose. Therefore, we synthesized CyMe-GlcIFG, which bears
a bulky cyclohexylmethyl substituent at the same position, in the
expectation that it should be impervious to α-glucosidase II ac-
tivity yet still bind to MANEA.
Isothermal titration calorimetry revealed that GlcIFG binds to
MANEA-Δ97 with a Kd of 19.6 ± 5.6 nM and to ManIFG with a
Kd of 170 ± 32 nM. While we were encouraged by preliminary
studies on a bacterial MANEA homolog showing that CyMeGlc-IFG
bound better than GlcIFG alone (Kd, 284 nM vs. 625 nM), on the
human enzyme, CyMe-GlcIFG bound less tightly than GlcIFG,
with a Kd of 929 ± 52 nM (SI Appendix, Fig. S1E), consistent with
structural features observed subsequently (see below). GlcDMJ,
previously reported to have IC50 values of 1.7 to 5 μM (35, 38), was
the weakest binding of the four compounds, with a Kd value of
1,020 ± 36 nM. Thus, MANEA exhibits a preference for inhibitors
that match the stereochemistry of the substrate −2/−1 residues
(GlcIFG vs. ManIFG), which is the reverse of the preference of
bacterial endo-α-1,2-mannanases for the same inhibitors (i.e., for
BtGH99: GlcIFG Kd = 625 nM; ManIFG Kd = 140 nM) (30).
Consistent with previous findings in bacterial GH99 enzymes, IFG
is preferred to DMJ in the −1 subsite.
The 3D Structure of Human MANEA Sheds Light on Eukaryotic Enzyme
Specificity. Crystals of human MANEA-Δ97 (Fig. 3A) were
obtained in several crystal forms (SI Appendix, Experimental
Procedures). The initial crystal form, in space group P21212,
diffracted to ∼2.25 Å resolution, and structure solution by mo-
lecular replacement (using BxGH99 as a search model) was
successful, leading to structures with R/Rfree 18%/22% (SI Ap-
pendix, Table S1). Unfortunately, this crystal form suffered from
occlusion of the active center by the His6-tag and a metal ion
assumed to be Ni2+. A second crystal form, P43212, provided
data of lower resolution (3 Å), but in this case we could build a
loop (131 to 141) absent in the first crystal form; however, this
crystal form could not be reliably reproduced. A third crystal
form in space group P62 was obtained with Anderson−Evans
polyoxotungstate [TeW6O24]
6− (TEW), which has been used on
Fig. 2. Substrates and inhibitors for MANEA inspired from the structure of the glucosylated N-glycan substrate. (Inset) Structure of Glc3Man9GlcNAc2
showing the cleavage site of MANEA.




























































occasion in protein crystallography to act as a linking agent be-
tween molecules in the crystal lattice; examples include Protein
Data Bank ID codes 4OUA, 4PHI, 4Z13, 6G3S, 6QSE, and
6N90 (reviewed in ref. 40). The new crystal form diffracted up to
1.8 Å resolution, generating largely anisotropic datasets. The
ligand-binding site was occupied by HEPES, with residues 191 to
201 poised to accept –2/–1 subsite ligands and +1/+2 subsites
open. The HEPES molecule was readily replaced by ligand
soaking (the IC50 for HEPES shows weak binding; SI Appendix,
Fig. S2), and we obtained a series of complexes including a bi-
nary complex of MANEA-Δ97 with GlcIFG, a ternary complex
with GlcIFG and α-1,2-mannobiose (structure and refinement
statistics in SI Appendix, Table S1) and a complex of an inactive
E404Q variant with a tetrasaccharide substrate.
The overall 3D structure of human MANEA is a single do-
main (β/α)8 barrel with a (partially; see below) open active center
in which Glu404 and Glu407 (human numbering, as part of a
conserved EWHE motif) are the catalytic residues in a neigh-
boring group participation mechanism that proceeds through an
epoxide intermediate (34) (Fig. 3 B and C). The structure is
similar (Cα rmsd >0.9 Å over 333 matched residues) to struc-
tures reported for BtGH99 and BxGH99 (31), with which
MANEA shares 40% sequence identity. The positions of the –2
to +2 ligands in the bacterial and human GH99 proteins are
equivalent and the sugar interactions in the –2 to +2 subsites, all
of which bind mannosides with identical linkages in both high-
mannose N-glycans (MANEA) and yeast mannan (bacterial
endo-α-1,2-mannanases) (29) are invariant.
A key difference between the substrates for the human and
bacterial GH99 enzymes are the –2 sugar residues, which is
glucose in high-mannose N-glycans, and mannose in yeast
mannan. These differences are achieved by differences in rec-
ognition between the human and bacterial GH99 enzymes in the
–2 subsite and its environs. In bacterial endo-α-1,2-mannanases,
Trp126 (numbering for BxGH99) (31) forms a hydrophobic in-
teraction with the C2 that was believed to be responsible for the
selectivity of bacterial enzymes for ManMan vs. GlcMan sub-
strates. In MANEA, the equivalent residue is Tyr189, which
makes a water-mediated interaction with O2 of Glc in the –2
subsite (Fig. 3 D and E). Notably, we observed a loop (residues
191 to 201, hereinafter the “–2 loop”), absent in the bacterial
structures, that was flexible and observed in different positions in
the different MANEA crystal forms (Fig. 3F).
Two residues within the –2 loop are invariant across animal
MANEAs: Asp195 and Gly198. Our structures reveal that
Asp195 forms a hydrogen bond with the 3-OH of the –2 sugar
(glucose) residue, and along with Asn197 H-bonding to O4, is a
key determinant of binding of GlcMan structures. The second
invariant residue, Gly198, enables the formation of a 195 to 198
turn, thereby allowing residues 195, 196, and 197 to form hy-
drogen bonds with the –2 sugar (Fig. 3 D and F).
MANEA isolated from human liver carcinoma cells processes
triglucosylated N-glycans at a lower rate than monoglucosylated
N-glycans (9). In the GlcIFG complex of MANEA, the –2 loop is
closed over the active site, and in this conformation, triglucosy-
lated N-glycans are unable to bind to human MANEA. However,
the other observed conformations show flexibility in the loop
that could allow these extended structures to bind. Of note,
bovine MANEA does not process triglucosylated N-glycans (9).
While both bovine and human MANEA have the –2 loop, a
Ser227 (human)-to-Lys change in the bovine enzyme was pro-
posed to have contributed to the difference in specificity. Ser227
lies adjacent to and points toward the –2 loop, while the side
chain of Lys226 (numbering as in bovine) may interact with the
loop and reduce its mobility (Fig. 3F). Interactions with the loop
may explain why CyMe-GlcIFG binds nearly 50-fold more
weakly than GlcIFG. Notably, bacterial GH99 endomannanases,
which act on complex extended yeast mannan substrates have
open active sites and do not contain this loop (SI Appendix, Fig.
S3). To test this hypothesis, we determined the structure of
BxGH99 with CyMe-GlcIFG (Kd of 339 nM; tighter binding than
that of GlcIFG alone, 625 nM). The cyclohexyl ring is visible (but
mobile) in the density, and indeed the loop in MANEA will
occlude binding of the cyclohexyl group (SI Appendix, Fig. S4)
Human MANEA as a Host Cell Antiviral Target. To explore the po-
tential of the endomannosidase pathway as an antiviral target, we
studied the effect of MANEA inhibitors on replication of
BVDV, a pestivirus of the Flaviviridae family. Reinfection assays
showed that increasing concentrations of GlcIFG, the tightest-
binding ligand of MANEA, resulted in a decrease in the number
of infected cells (measured as focus-forming units [FFUs])
Fig. 3. 3D X-ray structure of H. sapiens MANEA endomannosidase and its
complexes. (A) Domain structure of MANEA indicating the 98 to 462 domain
that was expressed. (B) 3D structure of MANEA, color-ramped from N (blue)
to C (red) terminus and with GlcIFG and α-1,2-mannobiose ligands shaded.
(C) Electron density for the ternary complex of MANEA with GlcIFG and
α-1,2-mannobiose. 2mFo-DFc synthesis contoured at 0.4 e–/Å3. (D) The –2
and –1 subsites of MANEA in complex with GlcDMJ, showing the interactions
and with key residues labeled. 2mFo-DFc synthesis contoured at 0.6 e–/Å3. (E)
The comparable –2 and –1 subsites of the bacterial endomannanase BxGH99
involved in yeast mannan degradation, in complex with ManIFG (Protein
Data Bank ID code 4V27). (F) Residues 189 to 203 containing the flexible loop
as observed in the MANEA-E404Q structure (cyan), MANEA+Ni2+ structure
(darker cyan), and MANEA with GlcIFG and α-1,2 mannobiose structure
(darkest cyan; ligand: gray). Hydrogen bonds with the –2 sugar are shown as
dashed lines.










































Fig. 4A. Previously, changes in the N-glycan structure of vesicular
stomatitis virus (VSV) G protein induced by the MANEA in-
hibitor GlcDMJ were identified by demonstrating a change in
susceptibility to hydrolysis by endo-β-N-acetylglucosaminidase
(endo H) (41). Therefore, we digested BVDV envelope glyco-
proteins E1/E2 with endo H.
Increased sensitivity of E1/E2 proteins to endo H cleavage was
observed in both GlcIFG and the glucosidase I/II inhibitor N-(6’-
[4″-azido-2″-nitrophenylamino]hexyl)-1–deoxynojirimycin
(NAP-DNJ), indicating an increased prevalence of high-mannose
N-glycans. The increased sensitivity for GlcIFG was greater than
that for NAP-DNJ, most likely reflecting the higher concentration
of the former. Treatment with a combination of GlcIFG andNAP-DNJ
provided an even greater sensitivity to endo H treatment, consistent
with more effective cessation of N-glycan processing by blocking the
glucosidase and endomannosidase pathways.
We next examined BVDV replication in the presence of a
combination of GlcIFG and NAP-DNJ (Fig. 4C). These data
showed that the combination of GlcIFG and NAP-DNJ gave a
greater reduction than either agent alone, suggesting an additive
antiviral effect from inhibiting both the α-glucosidase I/II and
endomannosidase pathways. The addition of NAP-DNJ not only
inhibits calnexin-mediated folding and quality control, but also
requires viral glycans to undergo processing by MANEA, hence
potentiating the antiviral effect.
To further define the antiviral potential of MANEA inhibi-
tors, we extended these studies to DENV. The MANEA inhib-
itors GlcIFG, GlcDMJ, CyMe-GlcIFG, and ManIFG were used
to study levels of viral particle formation and infectivity. Viral
particle formation, as assessed by secreted viral RNA, was un-
affected by treatment with MANEA inhibitors (Fig. 4D). How-
ever, treatment with GlcIFG, CyMe-GlcIFG, and GlcDMJ
caused a reduction in plaque number, demonstrating that dif-
ferences in glycosylation resulting from MANEA inhibition im-
pair DENV infectivity. The greatest effect was seen for GlcDMJ,
which reduced the number of plaque forming units by sixfold;
ManIFG had no effect. The antiviral effect observed was at a
relatively high concentration, but iminosugars are known to have
difficulty in gaining access to the secretory pathway (21).
This proof-of-principle study demonstrates that GlcDMJ is a
potential broad-spectrum antiviral, with changes in glycosylation
reducing infectivity of the progeny. As it is the weakest-binding
inhibitor, factors other than affinity, such as cell permeability,
may be responsible for the potency of antiviral effects.
Summary
We report the 3D structure of Golgi MANEA, a eukaryotic
N-glycosylation pathway glycosidase. The data provide a struc-
tural rationale for understanding the change in specificity of this
enzyme for monoglucosylated, diglucosylated, and triglucosy-
lated high-mannose N-glycans. We also show the potential for
MANEA inhibitors to alter N-glycan structures of viral envelope
glycoproteins and reduce viral infectivity. MANEA processes the
Glc1–3Man9GlcNAc2 structure and provides a pathway for gly-
coprotein maturation independent of the classical α-glucosidase
I/II–dependent pathways. Treatment of HBV with miglustat
(N-butyldeoxynojirimycin, an inhibitor of α-glucosidase II) im-
paired viral DNA secretion and led to aberrant N-glycans on M
Fig. 4. Antiviral action of MANEA inhibitors. Results of BVDV reinfection assays in MDBK cells (A, B, and C) and DENV reinfection assays in Huh7.5 cells (D and
E). (A) Percentage of FFU/mL relative to untreated cells at different concentrations of GlcIFG, at an MOI of 1. (B) Effect of MANEA inhibition (GlcIFG) and ER
glucosidase II inhibition (NAP-DNJ) on the susceptibility of glycans on the BVDV E1/E2 protein to cleavage by endoH. (C) The combined effects of NAP-DNJ and
GlcIFG on BVDV infectivity, as measured by FFU/mL. Experiments were performed in triplicate. (D) Secreted RNA levels in DENV-infected Huh7.5 cells. (E)
Reinfectivity plaque assay from DENV-infected Huh7.5 cells. The horizontal bar in D and E indicates the mean.




























































glycoprotein, but other viral glycoproteins displayed mature
glycans that arose through the endomannosidase pathway (23).
Conversely, GlcDMJ treatment of VSV led to changes in G
protein glycosylation (41).
These previous studies and the present work demonstrate that
different viral glycoproteins have varying degrees of dependence
on the α-glucosidase I/II and endomannosidase pathways for
maturation, and that inhibition of MANEA alone can alter the
infectivity of two encapsulated viruses. The human MANEA 3D
structure along with the demonstrated antiviral activity of disac-
charide imino and aza sugar inhibitors provide a foundation for
future inhibitor and drug development work. Given the devastat-
ing consequences of global outbreaks of viral disease, the present
work highlights the potential for MANEA as a new target for host-
directed antiviral agents exploiting viral glycoprotein biosynthesis.
Methods
The methodology of this study is described in more detail in SI Appendix.
Expression, Characterization, and Structure Solution. In brief, recombinant
MANEA-Δ97 featuring an N-terminal His tag was expressed in E. coli from a
pColdI system coexpressing the groEL and groES genes encoding the GroEL/ES
chaperone system. Recombinant MANEA-Δ97 was purified by metal-ion af-
finity and cation-exchange chromatography. Extensive crystal screening
identified five different crystal forms, with a condition including 1 mM TEW
allowing ligand-binding studies without an occluded active site. Structure
solution by molecular replacement and refinement featured programs from
the CCP4 suite (42). Structures and observed data have been deposited to
the Protein Data Bank. MANEA activity was determined by mass spectrom-
etry using GlcMan9GlcNAc2 as the substrate, with subsequent permethylation
and analysis by matrix-assisted laser desorption/ionization mass spectroscopy.
Michaelis–Menten kinetics was performed using a coupled assay with GlcMa-
n3OMe as the substrate (30). Ligand-binding thermodynamics were deter-
mined by isothermal titration calorimetry.
Viral Infectivity Studies. Madin–Darby Canine Kidney (MDBK) cells were in-
fected with BVDV at a multiplicity of infection (MOI) of 1, followed by in-
cubation with different concentrations of GlcIFG (0 to 1 mM) and in
combination with NAP-DNJ for 24 h. Cell culture medium was harvested, and
serial dilutions were made and used to infect naive MDBK cells. Cells were
incubated for 24 h, then washed and fixed with 4% (vol/vol) paraformal-
dehyde in PBS for 30 min. Following washing and blocking, cells were per-
meabilized and incubated with MAb103/105 (1:500 dilution in 5% milk-PBS;
Animal Health Veterinary Laboratories Agency) for 1 h. Incubation with anti-
mouse fluorescein isothiocyanate-conjugated secondary antibody (1:500 di-
lution in 5%milk-PBS; Sigma-Aldrich) and staining with DAPI allowed for the
counting of fluorescent foci and calculation of virus titers (in FFU/mL). The
samples obtained after treatment for 24 h were treated with Endo H and
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) under nonreducing conditions. The membrane produced fol-
lowing transfer was probed with MAb214 primary antibody and then visu-
alized with anti-mouse horseradish peroxidase secondary antibody (1:1,000;
Dako) for 1 h.
Huh7.5 cells were infected for 2 h with 50 μL of DENV2 strain 16681 at an
MOI of 0.1. The inoculum was removed and replaced with 200 μL of growth
medium with drug at the indicated concentrations in triplicate, and the in-
fected cells were incubated with drug for 2 d, after which the supernatant
was harvested. DENV RNA in cell culture supernatants was isolated using the
Direct-zol RNA MiniPrep Kit (Zymo Research) according to the manufac-
turer’s protocol and then assayed by qRT-PCR. Samples were read in tech-
nical duplicate and compared with a standard curve generated from high-titer
viral RNA isolated from C6/36-grown DENV2. The 95% confidence intervals
were determined based on biological and technical variations and graphed
using GraphPad Prism 6. The infectious DENV titers in supernatants collected
were evaluated by a plaque assay.
Data Availability.All study data are included in themain text and SI Appendix.
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